WhatsApp
backNews Article

Fischer Medical Ventures Raises Rs. 358.45 Crore via Preferential Share Issue and Warrants Conversion

Company allotted over 1 crore equity shares and converted 50.17 lakh warrants by September 30, 2026, as monitored by Infomerics Valuation and Rating

Fischer Medical Ventures Limited completed a preferential issue of equity shares and fully convertible share warrants, raising Rs. 358.45 crore for business growth. The company allotted 1.03 crore equity shares and converted 50.17 lakh warrants during the period ending September 30, 2026, with no deviations reported in fund utilization.

1 day ago|FISCHER+0.00%
Fischer Medical Ventures LimitedFISCHERPreferential Issue

Fischer Medical Ventures Limited

Preferential Issue

Fischer Medical Ventures Limited successfully raised Rs. 358.45 crore through a preferential allotment of equity shares and conversion of fully convertible warrants by September 30, 2026, with full compliance to the issuance objectives and no financial deviations.

The company issued 1,03,01,547 equity shares (post sub-division: 10,30,15,470 shares) and converted 50,17,000 warrants (post sub-division: 5,01,70,000) during the quarter ending September 30, 2026.

The preferential issue was priced at Rs. 234 per share/warrant (Rs. 23.40 post sub-division), aggregating Rs. 363.61 crore in total, with a net proceeds receipt of Rs. 358.45 crore after subscription and conversion.

Monitoring Agency Infomerics Valuation and Rating Limited reported no deviations from the intended use of funds as per SEBI regulations and the company’s offer document.

Warrants were issued with an 18-month conversion period from allotment dated February 18, 2025, with partial subscription payments received during fiscal quarters ending March 2026 and September 2026.

Highlights

  • Raised Rs. 358.45 crore through preferential issue and warrant conversion.
  • Issued 1.03 crore equity shares and converted 50.17 lakh fully convertible warrants.
  • Issue priced at Rs. 234 per share and warrant, post sub-division Rs. 23.40.
  • No deviations reported in fund utilization by Monitoring Agency.
  • 18-month conversion period for warrants from February 18, 2025, expiry August 17, 2026.
  • Monitoring conducted by Infomerics Valuation and Rating Limited as required by SEBI.

Key Data Snapshot

Total issue sizeRs. 358.45 crore
Equity shares allotted1,03,01,547 shares (10,30,15,470 post sub-division)
Warrants converted50,17,000 (5,01,70,000 post sub-division)
Issue price per share/warrantRs. 234 (Rs. 23.40 post sub-division)
Issue allotment date18 February 2025
Warrant conversion expiry date17 August 2026
Monitoring agencyInfomerics Valuation and Rating Limited

What happened

  • Fischer Medical Ventures Limited completed a preferential issue of equity shares and issuance of fully convertible share warrants aggregating Rs. 358.45 crore.
  • Allotment included 1.03 crore equity shares and conversion of 50.17 lakh warrants during the quarter ending September 30, 2026.
  • The issuance and fund utilization fully complied with SEBI ICIDR regulations and the company's offer document as confirmed by the monitoring agency.

Key details

  • The preferential issue price was Rs. 234 per share and warrant, translated to Rs. 23.40 post share sub-division among existing shareholders.
  • The issue period for warrants allows conversion up to 18 months from allotment dated February 18, 2025, expiring on August 17, 2026.
  • The preferential shares and warrants were issued to specified investors including promoters and promoter group members.
  • Partial subscription payment for warrants was received in fiscal quarters ending March 2026 and September 2026.
  • Total proceeds raised net of expenses amounted to Rs. 358.45 crore.
  • Monitoring agency provided an objective report confirming no financial or non-financial deviations in the use of raised funds.

Regulatory and governance context

  • The preferential issue and share warrants issuance followed SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  • Infomerics Valuation and Rating Limited was appointed as the Monitoring Agency as mandated under SEBI regulations to oversee utilization of proceeds and report quarterly performance.
  • No deviations from issuer’s stated use of funds were detected during the monitoring period ending September 30, 2026.

More News on Preferential Issue

View all

Latest corporate announcements and market updates in Preferential Issue.

View all news
Fischer Medical Ventures Raises Rs. 358.45 Crore via | Stockk News